Skip to main content

Table 4 Protein expression levels following small interfering RNA transfection

From: Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy

  siRNA CDK11 Cyclin L1α Cyclin L2α CK2α CK2α CK2β Caspase 3 – full length Bcl-xL Survivin
MDA-MB-231 siCDK11/CK2 0.09 ± 0.02 3.07 ± 1.56 0.73 ± 0.53 0.07 ± 0.08 0.05 ± 0.06 0.03 ± 0.03 0.45 ± 0.17 0.40 ± 0.38 0.73 ± 0.53
  P <0.0001    P <0.0001 P = 0.001 P <0.0001
  siCK2 0.98 ± 0.17 1.82 ± 0.67 0.78 ± 0.45 0.07 ± 0.07 0.05 ± 0.06 0.06 ± 0.04 0.85 ± 0.57 0.62 ± 0.10 0.85 ± 0.33
  P <0.0001 P = 0.001 P <0.0001
  siCDK11 0.04 ± 0.07 2.38 ± 0.18 0.91 ± 0.49 0.88 ± 0.17 1.13 ± 0.18 1.05 ± 0.15 0.57 ± 0.23 0.24 ± 0.05 0.79 ± 0.21
  P <0.0001 P = 0.022
  siControl 0.90 ± 0.04 1.77 ± 0.31 1.44 ± 0.62 1.09 ± 0.10 0.98 ± 0.26 1.14 ± 0.04 0.99 ± 0.07 0.93 ± 0.32 1.02 ± 0.20
SUM-149 siCDK11/CK2 0.44 ± 0.04 1.05 ± 0.12 1.30 ± 0.48 0.06 ± 0.05 0.27 ± 0.10 0.25 ± 0.14 0.45 ± 0.17 0.31 ± 0.21 0.77 ± 0.33
  P <0.0001 P <0.0001 P = 0.0004 P = 0.001 P = 0.036 P = 0.034
  siCK2 0.86 ± 0.13 0.93 ± 0.18 1.31 ± 0.52 0.08 ± 0.07 0.31 ± 0.23 0.14 ± 0.07 0.55 ± 0.34 0.73 ± 0.12 1.02 ± 0.10
  P <0.0001 P = 0.0007 P = 0.0004
  siCDK11 0.40 ± 0.16 1.04 ± 0.05 1.00 ± 0.19 1.19 ± 0.14 0.96 ± 0.12 0.77 ± 0.26 0.62 ± 0.23 0.54 ± 0.31 0.98 ± 0.18
  P <0.0001
  siControl 0.89 ± 0.12 0.89 ± 0.26 0.90 ± 0.87 1.36 ± 0.27 1.05 ± 0.29 0.88 ± 0.17 0.92 ± 0.24 1.08 ± 0.30 0.89 ± 0.22
  1. All values normalized to actin expression and expressed relative to untreated cells as mean ± standard deviation. P values are listed underneath the corresponding protein expression value for comparison with untreated cells if P <0.05. CDK, cyclin-dependent kinase; CK2, casein kinase 2; siRNA, small interfering RNA.